These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33252556)

  • 1. Intermittent Appearance of Antibodies to Infliximab Is Not Associated With Reduced Efficacy in Patients With Inflammatory Bowel Diseases.
    Awadie H; Waterman M
    J Clin Gastroenterol; 2022 Jan; 56(1):e47-e51. PubMed ID: 33252556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
    J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.
    Zitomersky N; Chi L; Liu E; Bray KR; Papamichael K; Cheifetz AS; Snapper SB; Bousvaros A; Silvester JA
    J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):261-271. PubMed ID: 38374555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.
    Ungar B; Chowers Y; Yavzori M; Picard O; Fudim E; Har-Noy O; Kopylov U; Eliakim R; Ben-Horin S;
    Gut; 2014 Aug; 63(8):1258-64. PubMed ID: 24041539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect.
    Raffáč Š; Gombošová L; Gabzdilová J; Novotná L; Šajtyová K; Pekárová T; Kopolovets I; Tóth Š
    Neuro Endocrinol Lett; 2017 Nov; 38(Suppl1):5-9. PubMed ID: 29200248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab levels and antibodies in IBD-related peripheral arthralgia.
    Levartovsky A; Ungar B; Yavzori M; Picard O; Fudim E; Eliakim R; Paul S; Roblin X; Ben-Horin S; Kopylov U
    Int J Colorectal Dis; 2020 Jun; 35(6):1141-1148. PubMed ID: 32296932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD.
    Zitomersky NL; Atkinson BJ; Fournier K; Mitchell PD; Stern JB; Butler MC; Ashworth L; Hauenstein S; Heiner L; Chuang E; Singh S; Bousvaros A
    Inflamm Bowel Dis; 2015 Feb; 21(2):307-14. PubMed ID: 25569737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.
    Lega S; Phan BL; Rosenthal CJ; Gordon J; Haddad N; Pittman N; Benkov KJ; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):134-141. PubMed ID: 29868777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THE EVALUATION OF INFLIXIMAB TROUGH LEVEL FAVORS MAINTENANCE THERAPY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Kampa KC; Loures MR; Ivantes CAP; Petterle RR; Pedroso MLA
    Arq Gastroenterol; 2023; 60(1):48-56. PubMed ID: 37194780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
    Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
    Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.
    Ungar B; Haj-Natour O; Kopylov U; Yavzori M; Fudim E; Picard O; Loebstein R; Lahat A; Maor Y; Avidan B; Lang A; Weiss B; Chowers Y; Eliakim R; Ben-Horin S
    Medicine (Baltimore); 2015 May; 94(18):e673. PubMed ID: 25950682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease.
    Vaughan R; Murphy E; Nalder M; Gibson RN; Ardalan Z; Boussioutas A; Christensen B
    Inflamm Bowel Dis; 2023 Jul; 29(7):1080-1088. PubMed ID: 36094156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Hofmekler T; Bertha M; McCracken C; Martineau B; McKinnon E; Schoen BT; McElhanon BO; Tenjarla G; Kugathasan S; Sauer CG
    J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.
    Pariente B; Pineton de Chambrun G; Krzysiek R; Desroches M; Louis G; De Cassan C; Baudry C; Gornet JM; Desreumaux P; Emilie D; Colombel JF; Allez M
    Inflamm Bowel Dis; 2012 Jul; 18(7):1199-206. PubMed ID: 22127789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.